Executives On The Move: New CEOs Named At DevaCell, Regeneus
Board directors appointed at AstraZeneca and Miragen Therapeutics, redesignated at Shanghai Fosun Pharma
You may also be interested in...
SK set for Korean trial with vaccine, as Biological E begins human trials of Baylor vaccine. Meanwhile, DongWha gets a Phase II nod for potential drug, and Celltrion progesses with Phase II regdanvimab trial.
Executive appointments at MyoKardia, Scancell Holdings and Sutro Biopharma
US FDA will hold 10 December advisory committee on Pfizer/BioNTech's just-filed application; the WHO issued a recommendation against Gilead's Veklury for hospitalized patients.